Clinical Trials Browser

Phase 2 × OTHER × Neoplasms by Histologic Type × Clear all

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

NCT04807166 2024-07-03

Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer

Phase 2 Active not recruiting

56 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial, Carcinoma, Endocrine System Diseases, Fallopian Tube Neoplasms, Genital Diseases, Female, Genital Neoplasms, Female, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Ovarian Diseases, Ovarian Neoplasms

NCT05252078 2022-12-16

ALTER-E005

Phase 2 Recruiting

30 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma, Carcinoma, Squamous Cell, Digestive System Diseases, Digestive System Neoplasms, Esophageal Diseases, Esophageal Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Squamous Cell

NCT05147493 2022-03-29

A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment

Phase 2 Unknown

51 enrolled

Plasma cell

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Renal Insufficiency, Neoplasms, Plasma Cell

NCT05298683 2022-03-28

A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor

Phase 2 Unknown

108 enrolled

Plasma cell

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Renal Insufficiency, Neoplasms, Plasma Cell

NCT05186558 2022-03-07

Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL

Phase 2 Unknown

54 enrolled

Lymphoid

Neoplasms by Histologic Type, Lymphoma, Large B-Cell, Diffuse

NCT04556071 2020-11-10

AVANIRA3

Phase 2 Unknown

32 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial, Adnexal Diseases, Carcinoma, Endocrine System Diseases, Endocrine Gland Neoplasms, Fallopian Tube Neoplasms, Genital Diseases, Female, Genital Neoplasms, Female, Gonadal Disorders, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Ovarian Diseases, Ovarian Neoplasms, Urogenital Neoplasms

NCT04566952 2020-10-30

ANLOLA

Phase 2 Unknown

68 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial, Adnexal Diseases, Carcinoma, Genital Diseases, Female, Genital Neoplasms, Female, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Ovarian Diseases, Ovarian Neoplasms, Urogenital Neoplasms

NCT01088815 2019-04-26

Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas

Phase 2 Completed

98 enrolled 14 charts

Gastrointestinal

Adenocarcinoma, Carcinoma, Digestive System Diseases, Digestive System Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Pancreatic Diseases, Pancreatic Neoplasms

NCT01037049 2018-09-17

Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks

Phase 2 Unknown

237 enrolled

Gastrointestinal

Adenocarcinoma, Carcinoma, Adenocarcinoma, Mucinous, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Rectal Diseases, Rectal Neoplasms, Colorectal Neoplasms, Neoplasms, Cystic, Mucinous, and Serous

NCT03351842 2017-12-19

Surgery With or Without Chemotherapy for Stage I NSCLC With Micropapillary Component ≥ 20%

Phase 2 Recruiting

460 enrolled

Thoracic

Adenocarcinoma of Lung, Neoplasms by Histologic Type

NCT01177007 2017-08-28

Intra-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid Tumors

Phase 2 Completed

50 enrolled 10 charts

EndocrineGastrointestinalNET

Adenocarcinoma, Carcinoma, Colonic Diseases, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Liver Diseases, Liver Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Glandular and Epithelial, Neoplasms, Nerve Tissue, Neoplastic Processes, Pathologic Processes, Rectal Diseases, Colorectal Neoplasms, Neuroectodermal Tumors, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT01215578 2015-04-30

NET

Phase 2 Terminated

33 enrolled

EndocrineGastrointestinalNET

Adenocarcinoma, Adenoma, Carcinoma, Digestive System Diseases, Digestive System Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Adenoma, Islet Cell, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Glandular and Epithelial, Neoplasms, Nerve Tissue, Pancreatic Diseases, Pancreatic Neoplasms, Neuroectodermal Tumors, Neuroendocrine Tumors

NCT01215565 2014-03-13

Fibrolam

Phase 2 Terminated

4 enrolled

Gastrointestinal

Fibrolamellar hepatocellular carcinoma, Adenocarcinoma, Carcinoma, Digestive System Neoplasms, Fibrosis, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Pathologic Processes

NCT01556815 2012-04-25

Sorafenib Combined With Transarterial Chemoembolization in Treating HBV-infected Patients With Intermediate Hepatocellular Carcinoma

Phase 2 Unknown

40 enrolled

Gastrointestinal

Adenocarcinoma, Carcinoma, Digestive System Neoplasms, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial

Clinical Trials

SPiReL

Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer

ALTER-E005

A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment

A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor

Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL

AVANIRA3

ANLOLA

Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas

Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks

Surgery With or Without Chemotherapy for Stage I NSCLC With Micropapillary Component ≥ 20%

Intra-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid Tumors

NET

Fibrolam

Sorafenib Combined With Transarterial Chemoembolization in Treating HBV-infected Patients With Intermediate Hepatocellular Carcinoma